Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.800
-0.130 (-3.31%)
At close: Jun 26, 2026, 4:00 PM EDT
3.930
+0.130 (3.42%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Molecular Partners AG Employees
Molecular Partners AG had 134 employees as of December 31, 2025. The number of employees decreased by 25 or -15.46% compared to the previous year.
Employees
134
Change (1Y)
-25
Growth (1Y)
-15.46%
Revenue / Employee
n/a
Profits / Employee
-$539,838
Market Cap
147.59M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Humacyte | 184 |
| Alpha Cognition | 71 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
| Enlivex | 34 |
| Jyong Biotech | 27 |
| TuHURA Biosciences | 22 |
MOLN News
- 4 weeks ago - Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 - GlobeNewsWire
- 4 weeks ago - Molecular Partners AG Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 4 weeks ago - Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit - GlobeNewsWire
- 6 weeks ago - Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 - GlobeNewsWire
- 6 weeks ago - Molecular Partners AG Earnings release: Q1 2026 - Filings
- 6 weeks ago - Molecular Partners AG Slides: Corporate presentation - Filings
- 7 weeks ago - Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences - GlobeNewsWire
- 2 months ago - Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling - GlobeNewsWire